Next Gen Diagnostics Announces New York State Department of Health’s Wadsworth Center Has Joined the NGD Cefiderocol Data Consortium for the Sequencing-Based Determination of Cefiderocol Resistance

November 19, 2024 8:00 AM

CAMBRIDGE, MA AND ALBANY, NY / ACCESSWIRE / November 19, 2024 / Next Gen Diagnostics (NGD), a world leader in the development of validated machine learning models for whole genome sequence- (WGS-) based determination of bacterial susceptibility to antibiotics, and the Wadsworth Center, New York State Department of Health's public health laboratory, today announce an agreement providing for Wadsworth to join the NGD Cefiderocol Data Consortium,...

Read more

Bionoid Pharma, Inc. Launches Enhanced Supplements Ltd. to Drive Strategic E-Commerce Expansion

November 19, 2024 7:30 AM

TORONTO, ON / ACCESSWIRE / November 19, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) is excited to announce the incorporation of its wholly owned subsidiary, Enhanced Supplements Ltd., a critical step in advancing the company's strategic transition to a robust e-commerce platform. This move is part of BINP's long-term growth plan to expand its market presence and diversify revenue streams.Enhanced Supplements Ltd. is specifically...

Read more

Adnexus Biotechnologies Inc. Appoints Dr. Hiroshi Ohrui to Scientific Advisory Board

November 19, 2024 7:00 AM

Adnexus Biotechnologies Inc. is pleased to announce the appointment of Dr. Hiroshi Ohrui to its Scientific Advisory Board. Dr. Ohrui is a distinguished expert in medicAinal chemistry and drug development, with a focus on antiviral therapies for HIV.Dr. Ohrui is best known for his pioneering work in the design and synthesis of Islatravir (formerly known as EFdA and MK-8591), an ultra-potent anti-HIV nucleoside drug in clinical development....

Read more

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

November 18, 2024 8:30 AM

Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.Event: Q4 Investor SummitPresentation Time: 10:30am - 11:00am ETLocation: https://www.webcaster4.com/Webcast/Page/3075/51674The theme is 40 micro-cap companies with a catalyst and/or strong...

Read more

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

November 18, 2024 8:00 AM

Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse eventsPhase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in...

Read more

CaaMTech's Psychedelic Functional Unblinding Strategy Gets Regulatory Blessing

November 14, 2024 5:05 PM

CaaMTech's New Clinical Trial Design Solves the Emergent Functional Unblinding Problems Plaguing Psychedelic Medicine DevelopersISSAQUAH, WA / ACCESSWIRE / November 14, 2024 / CaaMTech, Inc. is pleased to announce positive feedback from United States federal government regulators for its CT-4201 psilocin prodrug program. Amongst other topics, the regulator's feedback validated CaaMTech's plan for functional unblinding of its CT-4201 drug trials....

Read more

Cloud Storage Security Launches Antimalware for Azure Blob

November 14, 2024 11:00 AM

Cloud Storage Security (CSS), a leader in advanced threat detection and data loss prevention for cloud-native applications, today announced availability of its multi-cloud antimalware solution supporting data stored on the Microsoft Azure and Amazon Web Services (AWS) platforms. CSS's multi-cloud solution provides a unified console to manage malware and virus scanning across both platforms in most regions, and is available for purchase through...

Read more

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline

November 14, 2024 8:30 AM

POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders. IGC Pharma, Inc. ...

Read more

Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 14, 2024 8:30 AM

Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the third quarter ended September 30, 2024, and provided an update on recent business developments.Recent Milestones & Q3 Business HighlightsMerger Completion : On August 15, 2024, Silexion completed its business combination with Moringa...

Read more

Enalare Therapeutics is Granted a New Patent for ENA-001, Extending Its Exclusivity in the U.S. to 2043

November 14, 2024 8:00 AM

The New Patent Covers ENA-001 Methods of Treating Respiratory Depression Caused by Propofol, a Widely Used, Centrally Acting AnestheticPRINCETON, NJ / ACCESSWIRE / November 14, 2024 / Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health emergencies, today announced that the U.S. Patent and Trademark Office...

Read more

Vicore to Present at Upcoming Investor Conferences

November 14, 2024 2:20 AM

STOCKHOLM, SE / ACCESSWIRE / November 14, 2024 / Vicore Pharma Holding (STO:VICO)Stockholm, November 14, 2024 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:Stifel 2024 Healthcare ConferenceLocation: New York, United StatesPresenter: Ahmed Mousa, CEOPresentation Date and Time:...

Read more

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

November 13, 2024 8:30 AM

FRAMINGHAM, MA / ACCESSWIRE / November 13, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of 2024. "Over the course of the past quarter, we have continued to make progress advancing our DNase platform. Our focus is to leverage...

Read more

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

November 13, 2024 8:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric nanoparticles created for carrying therapeutic and targeting agents. With particular utility in...

Read more

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

November 12, 2024 4:15 PM

SAN DIEGO, CA / ACCESSWIRE / November 12, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the third quarter ended September 30, 2024.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our team...

Read more

Lifeloc Reports Third Quarter 2024 Results

November 12, 2024 4:13 PM

Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2024.Third Quarter Financial HighlightsLifeloc posted quarterly net revenue of $2.087 million in the third quarter of 2024, resulting in a quarterly net loss of $(158) thousand, or $(0.06) per diluted share. These results compare to net...

Read more

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

November 12, 2024 1:00 PM

Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.Event: Q4 Investor SummitPresentation Time: 9:00am - 9:30am ETLocation: https://www.webcaster4.com/Webcast/Page/3075/51643The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.Take a...

Read more

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

November 12, 2024 9:00 AM

Data presented at Society for Immunotherapy of Cancer (SITC) 2024Systemic DNase I combined with 𝛼-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against microsatellite stable, mismatch repair proficient colorectal carcinoma (CRC) tumorsFRAMINGHAM, MA / ACCESSWIRE / November 12, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on...

Read more

Inner State, Inc. Launches Research Project With The Ohio State University to Identify Psilocybin Mushroom Genetics, Novel Extracts, and Serotonin Receptor Binding Affinity Research to Discover New Bioactive Compounds

November 12, 2024 8:00 AM

COLUMBUS, OH / ACCESSWIRE / November 12, 2024 / Inner State, Inc., a women's health and wellness research and development company, and The Ohio State University announce the initiation of a research project to identify psilocybin mushroom genetics, novel extracts, and potential bioactivity. This research focuses on isolating fungi and evaluating their serotonin receptor binding affinity in an attempt to discover new medicinal natural...

Read more

Bionoid Pharma, Inc. Signs Binding Letter of Intent to Acquire Main E-Commerce Platform of Your Supplement Supply Store Ltd.

November 12, 2024 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is excited to announce the signing of a Binding Letter of Intent (LOI) with Your Supplement Supply Store Ltd. to acquire its leading e-commerce platform, EnhancedSupplements.net. This acquisition marks a pivotal step in Bionoid's strategic growth plan to accelerate its expansion into the health and wellness sector, supported by a scalable e-commerce platform that can be seamlessly enhanced with...

Read more

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

November 11, 2024 8:15 AM

Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 monthsBiomarker analysis confirms immune activation in the tumor microenvironmentData Presented at Society for Immunotherapy of Cancer on November 8, 2024LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / November 11, 2024 / Alligator Bioscience AB ("Alligator") (STO:ATORX)(ATORX) and Aptevo Therapeutics...

Read more